360关系网 - 360微门户 - 360度的人脉

头孢他啶 (Ceftazidime)

加入本微门户

微门户首页

	In Hospital-Acquired Pneumonia, Thought Leaders' Opinions and Clinical Data ... - PR Newswire (press release) 0条评论已读[79] 发布： 2013/05/15 17:44:07 PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
更多
	In Hospital-Acquired Pneumonia, Thought Leaders' Opinions and Clinical Data ... - PR Newswire (press release) 0条评论已读[83] 发布： 2013/05/14 17:32:58 PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
更多
	Markman Hearing A Likely Clearing Event For Cubist - Decision Any Day - Seeking Alpha 0条评论已读[525] 发布： 2013/05/14 17:10:28 Seeking Alpha Both are multicenter, randomized, double-blind, double-dummy studies, each targeting enrollment of 776 patients and evaluating CXA-201 versus a comparator drug, levofloxacin . The endpoint in both studies is non-inferiority to levofloxacin , which will ...
更多
	跟踪最热门制药公司44亿募投 6公司项目进展缓慢 0条评论已读[354] 发布： 2013/05/14 15:26:40 常山肝素系列产品产业化项目募集资金50000万元,已投金额12193万元,占比24.39%。肝素钠原料药(注射级)为精制肝素原料药,是常山公司的核心项目。该项产品目前已经...
更多
	跟踪制药公司44亿募投：以岭力生常山节奏缓慢 - 股城网 0条评论已读[254] 发布： 2013/05/13 17:30:52 股城网主力产品AE-活性酯、头孢克肟侧链酸活性酯、头孢他啶侧链酸活性酯、呋喃铵盐是重要的头孢类侧链医药中间体，其市场规模合计占头孢侧链中间体市场总规模的35%左右，对应下游头孢抗生素占世界头孢抗生素市场总规模的40 ... and more »
更多
	In Hospital-Acquired Pneumonia, Thought Leaders' Opinions and Clinical Data ... - PR Newswire (press release) 0条评论已读[87] 发布： 2013/05/13 17:30:51 PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
更多
	跟踪最热门制药公司44亿募投 \|投资\|A股\|证券_新浪财经_新浪网 0条评论已读[326] 发布： 2013/05/13 15:21:42 肝素钠原料药(注射级)为精制肝素原料药,是常山公司的核心项目。该项产品目前... 公司证券代表李新表示:常山对首次公开发行的募投项目进行了延期,其中“精制肝素...
更多
	跟踪最热门制药公司：其实只有两个主角(附股) - 凤凰网 0条评论已读[287] 发布： 2013/05/12 23:40:52 凤凰网该项产品目前已经通过了我国SFDA和欧盟药政管理机构EDQM的双重认证，可出口至欧盟地区，正在积极申请美国 FDA认证。肝素系列产品最近三年内实现销售收入占公司当期营业收入比例分别为94.87%、91.23%和98.07%。肝素钠 ... and more »
更多
	机构最新动向揭示周五挖掘20只黑马股 0条评论已读[133] 发布： 2013/05/12 17:37:06 600572,股吧)(600572)布洛芬颗粒的全国总代,收购一类新药头孢他啶他唑巴坦钠(3...DCF 估值分析公司合理价值为13.9元/股,现在价格12.20 元/股,有一定程度的...
更多
	In Hospital-Acquired Pneumonia, Thought Leaders' Opinions and Clinical Data ... - PR Newswire (press release) 0条评论已读[91] 发布： 2013/05/12 17:36:53 PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
更多

« 上一页 | 查看结果91-100共119 | 下一页 »

新闻分类

Industry News

政策法规

市场分析

企业动态

行业评论

人物访谈

新闻标签：

没有标签

最新报告

求职招聘